Asia-Pacific clinical trial imaging market is projected to register a substantial CAGR in the forecast period of 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.
Market Segmentation:
By Product & Services (Services, Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-Ray, Ultrasound, Optical Coherence Tomography, Others), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Hematology, Others ), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic and Government Research Institutes, Medical Device Manufacturers, Others), Distribution Channel (Direct Sales, Tender Sales), Country (China, Japan, India, Australia, Singapore, Indonesia, Thailand, South Korea, Malaysia, Philippines, Rest of Asia-Pacific)
Some of the major factors contributing to the growth of Asia-Pacific clinical trial imaging market:

- Increasing aging population
- Improving healthcare infrastructure

Market Players:

The key market players for Asia-Pacific clinical trial imaging market are listed below:

- BioTelemetry, Inc
- IXICO plc
- Resonance Health
- Bioclinica, ICON plc
- Radiant Sage LLC
- Lyscaut Medical Imaging Company
- Quotient Sciences
- worldcare Clinical
- Navitas Life Sciences
- Cardiovascular Imaging Technologies
- Intrinsic Imaging
- Image Core Lab
- ERT Clinical
- Perspectum Diagnostics
- Anagram 4 clinical trials
- Parexel International Corporation